Q4 2025 BeOne Medicines AG Earnings Call Transcript

Feb 26, 2026 / 01:00 PM GMT

Release Date Price: $322.37 (-8.48%)

Transcript 10-K8-K

Key Points

Positve

BeOne Medicines Ltd (ONC) achieved significant product revenue growth, GAAP profitability, and meaningful cash flow generation in 2025.
Brukinza, their foundational BTK inhibitor, became the number one product both in the US and globally, setting a new standard for efficacy and safety in CLL.
The company reported a 32% year-over-year growth in product revenue for Q4 2025, with Brukinza's global revenues growing by 49% for the full year.
BeOne Medicines Ltd (ONC) has a strong pipeline with multiple assets achieving clinical proof of concept and advancing towards registration.
The company is expanding its leadership in CLL and other hematological malignancies, with plans to establish itself as an oncology powerhouse in solid tumors.

Negative

The fixed duration therapies currently available have limitations, including underwhelming efficacy and safety concerns, which have limited their uptake and approval.
There are concerns about the long-term outcomes of fixed duration therapies compared to continuous BTK inhibitors like Brukinza.
The company faces competition from other BTK inhibitors and fixed duration therapies, which could impact market share and pricing dynamics.
There is uncertainty regarding the timing and magnitude of potential tax benefits from the reversal of deferred tax assets.
The company acknowledges that it is still a young player in the immunology space and needs to identify cornerstone assets to build around in the next few years.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

688235.SS - BeOne Medicines AG
Q4 2025 BeOne Medicines AG Earnings Call
Feb 26, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone.

Welcome to B1 Medicine's Q4 and full year 2025 earnings call webcast. All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question-and-answer session.

At this time, I would like to turn the call over to the company.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello and welcome. Thanks for joining us today. I'm Dan Mallor, head of investor relations at B1 Medicines. Before we begin, please note that you can find additional materials, including a replay of today's webcast

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.